Morningstar
•
Nov 03, 2026
Pfizer Inc.: Pfizer Earnings: Our Pipeline View Is Incrementally Positive; Maintaining Fair Value Estimate
Summary
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: GE Aerospace
Nov 05, 2026
•
GE
Analyst Report: The Walt Disney Company
Nov 05, 2026
•
DIS
Analyst Report: Bristol-Myers Squibb Co
Nov 04, 2026
•
BMY
Market Update: BKNG, AMD, BMY, MMM, OKE, PFE, WMB, ANET
Nov 04, 2026
•
ANET, AMD, OKE, MMM, BKNG, WMB, PFE, BMY
Analyst Report: Amgen Inc.
Nov 04, 2026
•
AMGN
Analyst Profile
Karen Andersen
Sector Strategist
Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is responsible for biotechnology research.Before joining Morningstar in 2005, Andersen received a master’s degree in business administration from Rice University, where she served as senior healthcare analyst for the M.A. Wright Fund and earned the distinction of Jones Scholar. She has scientific research experience in both academia (at Rice University and the University of Queensland in Australia) and industry (at Lexicon Genetics and a subsidiary of Genzyme).Andersen also holds a bachelor’s degree in biochemistry from Rice University, where she graduated magna cum laude. She is a member of Phi Beta Kappa and holds the Chartered Financial Analyst® designation. She ranked first in the biotechnology industry, and had the highest score overall, in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.
